Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 6 min ago
Peer-reviewedCC BY-NC 4.0Clinical and Experimental Pediatrics

Evidence-based clinical practice guidelines for pediatric hepatoblastoma: a systematic review and expert recommendations from Korea

9 affiliations
  1. 1Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
  2. 2Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  3. 3Division of Pediatric Surgery, Severance Children's Hospital, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
  4. 4Department of Pediatric Surgery, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Korea
  5. 5Department of Pediatrics, Inha University Hospital, Incheon, Korea
  6. 6Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  7. 7Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
  8. 8Division of Healthcare Research, National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, Korea
  9. 9Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Korea

Abstract

Hepatoblastoma (HB) is the most common primary liver malignancy in children, predominantly affecting those younger than 3 years of age. Although the overall survival rate has improved significantly over the past few decades, standardized clinical practice guidelines for HB in Korea have been lacking. This clinical practice guideline was developed to provide evidence-based recommendations for the diagnosis and treatment of HB in children. A multidisciplinary working group comprising pediatric hematologists/oncologists, radiologists, surgeons, pathologists, and methodologists systematically reviewed the literature published up to May 2023. For pretreatment imaging, both abdominal computed tomography and magnetic resonance imaging are useful for PRE-Treatment EXTent of disease (PRETEXT) staging, with each modality offering distinct advantages. PRETEXT staging at diagnosis is recommended as it provides valuable prognostic information. For standard-risk HB (PRETEXT I–III without metastasis and alpha-fetoprotein ≥100 ng/mL), cisplatinbased chemotherapy without doxorubicin is recommended over cisplatin-doxorubicin combination therapy, as it demonstrates equivalent survival outcomes with fewer adverse effects. In carefully selected patients who are eligible for complete resection at diagnosis, upfront surgery without neoadjuvant chemotherapy should be considered to spare unnecessary chemotherapy and its toxicities. For patients with residual pulmonary metastases after chemotherapy, pulmonary metastasectomy should be considered. Sodium thiosulfate administration following cisplatin should be considered to reduce ototoxicity, although the supporting evidence is derived predominantly from standard-risk patients and its availability in Korea remains limited. Regarding histological subtypes, well-differentiated fetal HB is associated with favorable outcomes and may be treated with surgery alone, whereas the small cell undifferentiated pattern is no longer classified as a HB subtype and requires immunohistochemical and molecular testing to distinguish it from malignant rhabdoid tumor and other small round cell tumors. This guideline represents the first evidence-based clinical practice guideline for pediatric HB in Korea. It aims to standardize the diagnostic and therapeutic approaches, ultimately improving outcomes for Korean children with HB. Given the rarity of this tumor, international collaboration and prospective data collection remain essential for future guideline updates.

Related

  1. Variation in recommendations for management of pediatric fever and neutropenia across databases and languages: A systematic review of clinical practice guidelines
    Asher Hancock, Brandon Fickling, Tea Reljic +4
    PLOS OnePeer-reviewedCC BY 4.0Full textInfectious diseaseOncologyPLOSPMC
  2. Global perspectives on dietary management of small intestinal bacterial overgrowth (SIBO): a systematic review of clinical guidelines, consensus statements and expert recommendations
    Magdalena Jodkiewicz, Justyna Malinowska, Karolina Marek-Woźny
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. European Interdisciplinary Guidelines on Pain Management in Acute Pancreatitis: UEG, EPC, EDS, ESDO, EAGEN, ESPGHAN, ESGAR, and ESPCG Evidence-Based Recommendations
    Sanjay Pandanaboyana, Cecilie Siggaard Knoph, Louise Kuhlmann +9
    United European Gastroenterology JournalPeer-reviewedCC BY-NC-ND 4.0Full textSurgery & anaesthesiaHAL
  4. Comparison of national and international pediatric fever clinical practice guidelines: A systematic review
    Momčilo T Pavlović, Karolina F Berenji, Zeljko L Rokvic
    World Journal of Clinical PediatricsPeer-reviewedCC BY-NC 4.0Full textClinical trials & evidence synthesisPMC
  5. Syndrome-oriented CNS infectious complications after hematopoietic stem-cell transplantation and CAR T-cell therapy, part 1—viral encephalitis, meningitis, and myelitis: recommendations from the Practice Harmonization & Guidelines Committee of the EBMT
    José Luis Piñana, Simone Cesaro, Jan Styczynski +12
    eClinicalMedicinePeer-reviewedCC BY 4.0General medicineCrossref
BibTeX
@article{suh2026evidencebased,
  title = {{Evidence-based clinical practice guidelines for pediatric hepatoblastoma: a systematic review and expert recommendations from Korea}},
  author = {Jin Kyung Suh and Jisun Hwang and Hee Mang Yoon and Kyong Ihn and Jung-Man Namgoong and Jeong A. Park and Jung-Sun Kim and Hyoung Soo Choi and Sung Hye Park and Dong Ah Park and Kyung-Nam Koh},
  journal = {Clinical and Experimental Pediatrics},
  year = {2026},
  month = oct,
  doi = {10.3345/cep.2026.02691},
  url = {https://doi.org/10.3345/cep.2026.02691},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Evidence-based clinical practice guidelines for pediatric hepatoblastoma: a systematic review and expert recommendations from Korea
AU  - Jin Kyung Suh
AU  - Jisun Hwang
AU  - Hee Mang Yoon
AU  - Kyong Ihn
AU  - Jung-Man Namgoong
AU  - Jeong A. Park
AU  - Jung-Sun Kim
AU  - Hyoung Soo Choi
AU  - Sung Hye Park
AU  - Dong Ah Park
AU  - Kyung-Nam Koh
PY  - 2026
DA  - 2026/10/23
JO  - Clinical and Experimental Pediatrics
DO  - 10.3345/cep.2026.02691
UR  - https://doi.org/10.3345/cep.2026.02691
AB  - Hepatoblastoma (HB) is the most common primary liver malignancy in children, predominantly affecting those younger than 3 years of age. Although the overall survival rate has improved significantly over the past few decades, standardized clinical practice guidelines for HB in Korea have been lacking. This clinical practice guideline was developed to provide evidence-based recommendations for the diagnosis and treatment of HB in children. A multidisciplinary working group comprising pediatric hematologists/oncologists, radiologists, surgeons, pathologists, and methodologists systematically reviewed the literature published up to May 2023. For pretreatment imaging, both abdominal computed tomography and magnetic resonance imaging are useful for PRE-Treatment EXTent of disease (PRETEXT) staging, with each modality offering distinct advantages. PRETEXT staging at diagnosis is recommended as it provides valuable prognostic information. For standard-risk HB (PRETEXT I–III without metastasis and alpha-fetoprotein ≥100 ng/mL), cisplatinbased chemotherapy without doxorubicin is recommended over cisplatin-doxorubicin combination therapy, as it demonstrates equivalent survival outcomes with fewer adverse effects. In carefully selected patients who are eligible for complete resection at diagnosis, upfront surgery without neoadjuvant chemotherapy should be considered to spare unnecessary chemotherapy and its toxicities. For patients with residual pulmonary metastases after chemotherapy, pulmonary metastasectomy should be considered. Sodium thiosulfate administration following cisplatin should be considered to reduce ototoxicity, although the supporting evidence is derived predominantly from standard-risk patients and its availability in Korea remains limited. Regarding histological subtypes, well-differentiated fetal HB is associated with favorable outcomes and may be treated with surgery alone, whereas the small cell undifferentiated pattern is no longer classified as a HB subtype and requires immunohistochemical and molecular testing to distinguish it from malignant rhabdoid tumor and other small round cell tumors. This guideline represents the first evidence-based clinical practice guideline for pediatric HB in Korea. It aims to standardize the diagnostic and therapeutic approaches, ultimately improving outcomes for Korean children with HB. Given the rarity of this tumor, international collaboration and prospective data collection remain essential for future guideline updates.
SN  - 2713-4148
ER  -